Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone877-352-6261
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.07 billion
Profitability
Miscellaneous
Employees5,590
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable
Elanco Animal Health (NYSE:ELAN) Frequently Asked Questions
What is Elanco Animal Health's stock symbol?
Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."
How were Elanco Animal Health's earnings last quarter?
Elanco Animal Health (NYSE:ELAN) announced its quarterly earnings results on Wednesday, November, 6th. The company reported $0.30 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.26 by $0.04. The company had revenue of $771.30 million for the quarter, compared to analyst estimates of $765.85 million. Elanco Animal Health had a net margin of 3.04% and a return on equity of 7.79%. The firm's revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.29 earnings per share. View Elanco Animal Health's Earnings History.
When is Elanco Animal Health's next earnings date?
What guidance has Elanco Animal Health issued on next quarter's earnings?
Elanco Animal Health updated its FY19 earnings guidance on Wednesday, November, 6th. The company provided earnings per share (EPS) guidance of $1.04-1.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.08. The company issued revenue guidance of $3.07-3.085 billion, compared to the consensus revenue estimate of $3.10 billion.
What price target have analysts set for ELAN?
10 Wall Street analysts have issued twelve-month price objectives for Elanco Animal Health's shares. Their forecasts range from $28.00 to $37.00. On average, they anticipate Elanco Animal Health's share price to reach $32.59 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price. View Analyst Price Targets for Elanco Animal Health.
What is the consensus analysts' recommendation for Elanco Animal Health?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Elanco Animal Health.
Has Elanco Animal Health been receiving favorable news coverage?
Press coverage about ELAN stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Elanco Animal Health earned a news impact score of 1.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Elanco Animal Health.
Who are some of Elanco Animal Health's key competitors?
Some companies that are related to Elanco Animal Health include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Genmab A/S (GNMSF), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC) and Mylan (MYL).
What other stocks do shareholders of Elanco Animal Health own?
Who are Elanco Animal Health's key executives?
Elanco Animal Health's management team includes the folowing people:
- Mr. Jeffrey N. Simmons, Pres, CEO & Director (Age 52)
- Mr. Todd S. Young, Exec. VP & CFO (Age 47)
- Mr. David S. Kinard, Exec. VP of HR (Age 52)
- Ms. Sarena S. Lin, Exec. VP of Elanco USA, Corp. Strategy & Global Marketing (Age 48)
- Mr. David Alan Urbanek, Exec. VP of Manufacturing & Quality (Age 53)
When did Elanco Animal Health IPO?
(ELAN) raised $1.4 billion in an initial public offering (IPO) on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.
Who are Elanco Animal Health's major shareholders?
Elanco Animal Health's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (4.10%), State Street Corp (2.62%), TimesSquare Capital Management LLC (0.42%), California Public Employees Retirement System (0.39%), Sumitomo Mitsui Trust Holdings Inc. (0.38%) and Krensavage Asset Management LLC (0.24%). Company insiders that own Elanco Animal Health stock include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View Institutional Ownership Trends for Elanco Animal Health.
Which major investors are selling Elanco Animal Health stock?
ELAN stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Pictet Asset Management Ltd., First Trust Advisors LP, TimesSquare Capital Management LLC, Nippon Life Global Investors Americas Inc., Voya Investment Management LLC, State of New Jersey Common Pension Fund D and Daiwa Securities Group Inc.. View Insider Buying and Selling for Elanco Animal Health.
Which major investors are buying Elanco Animal Health stock?
ELAN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Vantage Investment Partners LLC, Sumitomo Mitsui Trust Holdings Inc., Millennium Management LLC, Sector Gamma AS, General American Investors Co. Inc., California Public Employees Retirement System and Cullen Frost Bankers Inc.. Company insiders that have bought Elanco Animal Health stock in the last two years include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View Insider Buying and Selling for Elanco Animal Health.
How do I buy shares of Elanco Animal Health?
Shares of ELAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Elanco Animal Health's stock price today?
One share of ELAN stock can currently be purchased for approximately $27.16.
How big of a company is Elanco Animal Health?
Elanco Animal Health has a market capitalization of $10.13 billion and generates $3.07 billion in revenue each year. The company earns $86.50 million in net income (profit) each year or $1.18 on an earnings per share basis. Elanco Animal Health employs 5,590 workers across the globe.View Additional Information About Elanco Animal Health.
What is Elanco Animal Health's official website?
How can I contact Elanco Animal Health?
Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company can be reached via phone at 877-352-6261.
MarketBeat Community Rating for Elanco Animal Health (NYSE ELAN)
MarketBeat's community ratings are surveys of what our community members think about Elanco Animal Health and other stocks. Vote "Outperform" if you believe ELAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
